Novo Nordisks new oral GLP-1, Wegovy pill, is a once-daily pill offering comparable weight-loss results (an average of 13.6% of your body weight) to injectable Wegovy.^ ^Eligible patients lost an average of 13.6% of their body weight in a 64-week clinical trial evaluating 25 mg oral semaglutide compared to those on 2.4 mg injectable semaglutide who lost an average of 14.9% of their body weight in a 68-week clinical trial
Ongoing valuereloads, free spins, enhanced oddskeeps momentum without pushing irresponsible behavior
B12 injections are intended to restore optimal levels of this important vitamin to alleviate symptoms of deficiency
Yet week after week, the scale barely budged
Pre-clinical data show citrulline preserving nephron architecture and reducing inflammation in diabetic models, but human evidence is absent, so thorough renal monitoring is mandatory
Glickman say a good place to start is with modifiable lifestyle factors such as sleep, nutrition, and physical activity